Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 544 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in... September 27, 2024 ESMO Announces Results of 2025 Elections June 14, 2025 ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of... July 1, 2025 Luspatercept Improves the Rate of RBC Transfusion Independence Compared with Epoetin... June 19, 2023 Load more HOT NEWS Immunotherapy approved for some people with advanced melanoma in England Research with integrity – why building networks is vital for integrity How Breast Cancer Risk Assessment Tools Work Opinion: “We’ve been pushing for change for 20 years. We’re not...
